FDA Peptide Regulations in 2026: What’s Changing—and What It Means Right Now
There have been a lot of headlines this year about peptides — BPC-157, TB-500. Headlines include: Are these legal now? Illegal? What's actually going on?
It's a fair question because the coverage has been confusing, and a lot of it blurs together several separate regulatory steps that happened months apart. I want to walk you through what has actually happened so far in 2026, what it does and doesn't mean, and where things stand right now. This is meant purely as an informational update — not a recommendation one way or the other about using peptides.
A Little Background First
To understand any of this, it helps to know how compounding works. Compounding pharmacies are allowed to prepare custom medications for individual patients, but they can only use certain bulk drug substances to do it. The FDA sorts nominated substances into categories: Category 1 substances can generally be compounded, Category 2 substances are restricted due to safety concerns, and Category 3 substances need more data before the FDA will even consider them. Separately, there's something called the 503A Bulks List — a list a substance must be on (or otherwise qualify for through an FDA-approved drug or an official pharmacopeia monograph) before it can legally be compounded at all.
Back in late 2023, the FDA placed 19 commonly used peptides — including BPC-157, TB-500, and others — onto the restricted Category 2 list because they cited safety concerns. Many clinicians and compounding pharmacies pushed back at the time, arguing the restriction wasn't clearly tied to a specific safety signal for most of the peptides involved. Regardless of where you land on that debate, the practical effect was straightforward: pharmacies that had been legally compounding these peptides had to stop, while patient demand for them did not go away — it largely shifted toward unregulated online sellers marketing research use only products with no quality oversight.
What Happened in 2026
February 27, 2026: HHS Secretary Robert F. Kennedy Jr., who has spoken publicly about his own use of peptides, announced that around 14 of the 19 restricted peptides would be moved back to Category 1, intending to restore legal compounding access for patients with valid prescriptions.
April 15–16, 2026: The FDA followed through on part of that announcement. Twelve peptides came off the Category 2 list after the companies that had originally nominated them for restriction withdrew those nominations. This became effective April 23, 2026. It's worth being precise about what this step actually did: it removed those substances from the restricted list, but it did not automatically make them legal to compound. Removal from Category 2 is a necessary step but unfortunately it’s not a finish line.
July 23–24, 2026: This is the meeting that generated the most news coverage. The FDA's Pharmacy Compounding Advisory Committee (PCAC) met over two days at the agency's White Oak campus in Silver Spring, Maryland to formally review seven peptide substances — BPC-157, KPV, TB-500, and MOTS-c on the first day, and Emideltide (also known as DSIP), Semax, and Epitalon on the second — to decide whether to recommend adding them to the 503A Bulks List. After extensive testimony and debate, the committee voted, narrowly in most cases, to recommend six of the seven for inclusion. Emideltide was the one substance the panel did not recommend.
What This Vote Does — and Doesn't — Mean
Here's the piece that I think matters most, and the piece that most headlines glossed over: an advisory committee recommendation is not a law, a rule, or an FDA approval. It's exactly what it sounds like — advice. The FDA is not obligated to follow it, though the agency often does give these recommendations real weight. Notably, FDA's own scientific staff had recommended against adding any of the seven peptides, citing a lack of robust human safety and efficacy data — including trials on BPC-157 that reviewers described as too short and too small to draw firm conclusions from. The committee's vote went a different direction than that staff recommendation, which is part of why it drew so much attention.
For any of these substances to become legally compoundable, the FDA still has to decide whether to accept the committee's recommendation, and then go through formal notice-and-comment rulemaking: publishing a proposed rule, taking public comments, and issuing a final rule. That process can take a year or more. As of this writing, none of these seven peptides are legally compoundable, and the FDA can still take enforcement action against pharmacies that prepare them. There is one wrinkle worth knowing about: some legal analysts have pointed out that Secretary Kennedy may have authority, under a specific provision of the compounding law, to bypass the rulemaking process and place peptides directly into Category 1 if he determines it's necessary to protect public health. That hasn't happened as of this writing, but it's a possibility worth watching.
What's Next
The FDA has already scheduled another PCAC meeting, to take place before the end of February 2027, to review five additional peptides: cathelicidin (LL-37), GHK-Cu, dihexa acetate, melanotan II, and pegylated mechano growth factor (PEG-MGF). So this is very much an ongoing story, not a settled one.
My Take, As Your Naturopathic Doctor
I think it's genuinely encouraging that the FDA is taking a serious, structured look at these substances rather than leaving the conversation entirely to the gray market — because that gray market is real, and it carries its own risks: products with unverified purity, inconsistent dosing, and no medical oversight at all. At the same time, I don't think it serves anyone well to treat an advisory vote as if it were a green light. The FDA's own scientists raised real concerns about the depth of the safety data, and those concerns don't disappear just because a committee voted the way it did.
My honest recommendation, regardless of how the rulemaking plays out: this is a conversation to have with a licensed provider who can walk through the current legal and clinical picture with you, not something to sort out from a headline or a gray-market seller's product page. If you have questions about where things currently stand or whether peptide therapy makes sense in your specific situation, that's exactly the kind of conversation I'm happy to have with you in a telemedicine visit .
Sources
Ault, A. "FDA Expert Panel Backs Compounding of Six Peptides." Medscape, July 28, 2026.
"FDA Advisory Committee Endorses Compounding of Certain Peptides." Holland & Knight Insights, August 2026.
"FDA Panel Backs 6 Peptides for Compounding." AJMC, 2026.
"The Peptide Reclassification Everyone's Talking About: A Pharmacist's Take on What RFK Jr's Announcement Actually Means." Pharmacy Times, 2026.
"FDA Peptide Vote Explained: What Actually Happened." American Wellness Pharmacy Insights, 2026.
Snow, C.D. & Palmer, K.L. "FDA's Pep(tide) Rally! What Compounders and Industry Need to Know." The FDA Law Blog, April 21, 2026.
U.S. Food and Drug Administration, Pharmacy Compounding Advisory Committee meeting materials, July 23–24, 2026 (fda.gov).
Dr. Evelyn Cordova | Telemedicine Naturopath